计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
ABT-107 是选择性的 α7 神经元尼古丁受体的激动剂。ABT-107 对单侧 6-羟多巴胺损伤大鼠的黑质纹状体损伤起到保护作用。
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
In Vivo
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly,\n100%), and good CNS penetration in rodents with a brain/plasma ratio of 1 . ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB . ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S 9 -GSK3 and decreases p-tau in mouse cortex and hippocampus in mice . ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rats (male Sprague-Dawley; 350-380 g b.wt.) . Dosage: 1, 3 μmol/kg. Administration: I.P. daily for 3 consecutive days. Result: Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration. Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior. Animal Model: Female TAPP (and wild-type littermates) mice . Dosage: 1 mg/kg. Administration: Continuous subcutaneous infusion for 2 weeks. Result: Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice.
| ALogP | 2.6 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | A655699 |